Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in District of Columbia: - Local Institution - 2106 — Washington D.C., District of Columbia
- Local Institution - 2110 — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in District of Columbia: - Johns Hopkins University, Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Sponsor: AstraZeneca
NCT ID: NCT06792695
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT03998202
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal pol…
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05612347
Sites in District of Columbia: - MedStar Health — Washington D.C., District of Columbia
Recruiting Academic/Other
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surv…
Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
NCT ID: NCT02333604
Sites in District of Columbia: - Cancer Support Community Research & Training Institute — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This study is designed to assess the effect of implementing a text messaging strategy for colorectal cancer screening among homeless persons aged 45-75 years, who are not up to date on colorectal cancer screening, in shelter clinics in NYC…
Sponsor: George Washington University
NCT ID: NCT07220018
Sites in District of Columbia: - George Washington University — Washington D.C., District of Columbia